UNITED THERAPEUTICS Corp 4

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, exercised 9,500 stock options at $117.76 and sold 9,500 shares of common stock around $498–$509 per share via a 10b5-1 plan.

On September 10, 2026, Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, through a family trust, exercised 9,500 stock options for United Therapeutics common stock at an exercise price of $117.76 per share, acquiring 9,500 shares, and on the same day sold 9,500 shares of common stock in a series of open-market transactions at prices ranging from approximately $498.44 to $508.80 per share pursuant to a pre-arranged Rule 10b5-1 trading plan. The exercise generated stock valued at roughly $1.12 million at the sale prices, with an intrinsic gain of about $3.64 million versus the option strike price, while the gross sale proceeds totaled approximately $4.79 million across the multiple tranches. Following these transactions, the reporting person, through various direct and indirect holdings (including family trusts and spouse-held interests), reported beneficial ownership of 461,410 shares of United Therapeutics common stock, with the 9,500 newly issued shares held indirectly by a trust and an estimated post-transaction equity stake worth around $233 million based on the prevailing ~$505 per share trading price.

Filing Facts

CIK

1082554

Ticker

UTHR

Form

4

Source Type

fda

Accession

0001106578-26-000139

Alert Tier

7